0001140361-23-029141.txt : 20230609 0001140361-23-029141.hdr.sgml : 20230609 20230609163046 ACCESSION NUMBER: 0001140361-23-029141 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230601 FILED AS OF DATE: 20230609 DATE AS OF CHANGE: 20230609 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nguyen AnhCo CENTRAL INDEX KEY: 0001977970 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36548 FILM NUMBER: 231005789 MAIL ADDRESS: STREET 1: 2380 CONEJO SPECTRUM ST STREET 2: SUITE 200 CITY: THOUSAND OAKS STATE: CA ZIP: 91320 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Atara Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001604464 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 460920988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2380 CONEJO SPECTRUM ST STREET 2: SUITE 200 CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: 805-623-4244 MAIL ADDRESS: STREET 1: 2380 CONEJO SPECTRUM ST STREET 2: SUITE 200 CITY: THOUSAND OAKS STATE: CA ZIP: 91320 3 1 form3.xml X0206 3 2023-06-01 0 0001604464 Atara Biotherapeutics, Inc. ATRA 0001977970 Nguyen AnhCo C/O ATARA BIOTHERAPEUTICS, INC. 2380 CONEJO SPECTRUM STREET, SUITE 200 THOUSAND OAKS CA 91320 true EVP, Chief Sci. & Tech Officer Common Stock 301125 D Employee Stock Option (Right to Buy) 13.24 2023-05-10 2031-05-09 Common Stock 87124 D Employee Stock Option (Right to Buy) 13.24 2031-05-09 Common Stock 87125 D Employee Stock Option (Right to Buy) 10.21 2023-06-01 2032-02-29 Common Stock 35048 D Employee Stock Option (Right to Buy) 10.21 2032-02-29 Common Stock 77108 D Employee Stock Option (Right to Buy) 3.91 2023-06-01 2033-02-28 Common Stock 28907 D Employee Stock Option (Right to Buy) 3.91 2033-02-28 Common Stock 317988 D Includes an aggregate 270,072 restricted stock units ("RSUs"), which are comprised of: (i) 57,724 RSUs that vest as to 1/8th of shares on August 15, 2023 and each of the next seven (7) Quarterly Vesting Dates (as defined herein); (ii) 41,020 RSUs that vest as to 1/11th of shares on August 15, 2023 and each of the next ten (10) Quarterly Vesting Dates; (iii) 30,000 RSUs that vest as to 1/2nd of shares on August 15, 2023 and 1/2nd on August 15, 2024; and (iv) 141,328 RSUs that vest as to 1/11th of shares on August 15, 2023 and each of the next ten (10) Quarterly Vesting Dates, each of which is subject to the reporting person's continuous service. "Quarterly Vesting Date" means March 1, May 15, August 15, and November 15 of each year, provided that if such date falls on a weekend or holiday, the "Quarterly Vesting Date" shall be the first (1st) business day after such date. 1/24th of shares subject to the stock option vest and become exercisable on June 10, 2023, and the remaining shares vest in equal monthly installments over the following twenty-three (23) months, subject to the reporting person's continuous service. 1/33rd of shares subject to the stock option vest and become exercisable on July 1, 2023, and the remaining shares vest in equal monthly installments over the following thirty-two (32) months, subject to the reporting person's continuous service. Exhibit 24 - Power of Attorney /s/ Jeff Kiekhofer, Attorney-in-Fact for AnhCo Nguyen 2023-06-09 EX-24 2 brhc20054257_ex24.htm EXHIBIT 24
Exhibit 24

POWER OF ATTORNEY

The undersigned, as a Section 16 reporting person of Atara Biotherapeutics, Inc. (the "Company"), hereby constitutes and appoints Eric Hyllengren, Jeff Kiekhofer, Amar Murugan, John Chao and Kathleen Klaben the undersigned's true and lawful attorneys-in-fact to:

1.          Complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorneys-in-fact shall in their discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and

2.          Do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate.
 
The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

The undersigned hereby terminates all prior powers of attorney regarding the subject matter hereof.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of May 10, 2023.

 
Signature:
/s/ AnhCo Nguyen
     
   
AnhCo Nguyen